Vir Bio CEO on Cancer Treatment Progress, Potential Deals

Feb 27th, 2026Vir Bio CEO on Cancer Treatment Progress, Potential DealsVir Biotechnology Vir is a clinical-stage biopharmaceutical company focused on powering the immune system to transform lives by discovering and developing medicines for serious infectious diseases and cancer. The company on Monday announced new data from the ongoing Phase 1 clinical trial of VIR-5500, a prostate-specific membrane antigen (PSMA)-targeting, PRO-XTEN dual-masked T-cell engager (TCE) being evaluated in patients with advanced metastatic castration-resistant prostate cancer (mCRPC) who have progressed after multiple lines of therapy. These data suggest that VIR-5500 monotherapy is well tolerated and exhibits promising anti-tumor activity. Vir CEO Marianne De Backer discusses the progress being made with the firm's leading treatments, the runup in its share price thus far in 2026, and why partnerships are key to advancing Vir's impact. Dr. De Backer speaks with Carol Massar and Tim Stenovec on Bloomberg Businessweek Daily.Duration:0:29Trump Not Happy With How Iran Is NegotiatingDuration:3:14OpenAI Finalizes Funding Round at $730 Billion ValuationDuration:2:59TPG Has $59 Million Exposure to Collapsed Lender MFSDuration:3:49Anthropic Is in a Lose-Lose Situation, Opinion's Lee SaysDuration:3:09Netflix Drops Discovery Bid, Clearing Way for ParamountDuration:1:47US Producer Prices Climb in January, Pushed Higher by ServicesDuration:5:10Anthropic Escalates Pentagon AI FeudDuration:3:27What to Watch for on 'Bloomberg This Weekend'Duration:2:20What's Next for the Super Bowl?Duration:2:55London Credit Blowup Has Wall Street Firms ScramblingDuration:3:38Greens Win UK By-Election in Blow to Starmer's LabourDaybreak: EuropeDuration:2:58Hillary Clinton Says She Denied Ever Knowing Jeffrey EpsteinAvailable on:Listen onApple TVListen onRokuListen onSamsung TVListen onFire TVListen onAndroid TVListen onRakuten TVListen onHaystack NewsWatch BTV in your area:Channel Finder